U.S. markets closed

MediWound Ltd. (MDWD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.71000.0000 (0.00%)
At close: 4:00PM EDT

MediWound Ltd.

42 Hayarkon Street
Yavne 8122745
Israel
972 7 797 14100
http://www.mediwound.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Sharon Malka CPA, MBAChief Exec. Officer528kN/A1972
Prof. Lior RosenbergCo-Founder & Chief Medical Technology Officer405kN/A1946
Mr. Carsten HenkeChief Commercial Officer of Europe338kN/A1966
Dr. Ety KlingerChief R&D Officer350kN/A1962
Mr. Stephen T. Wills CPA, CPA, MSTExec. ChairmanN/AN/A1957
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Corporate Governance

MediWound Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.